Skip to content

Available 24/7 for Urgent On-Site or Virtual Consulting

  • (208) 971-6430
  • [email protected]

FDA Inspections

Consulting and Compliance

  • Industries
    • Biologics
    • Cosmetics
    • Dietary Supplements
    • Medical Devices
    • Pet Food and Animal Health
    • Pharmaceuticals
  • Services
    • FDA 483 Response Consulting
    • FDA Inspection Facilitation Services
    • FDA Inspection Readiness Services
    • FDA Inspection Training
    • FDA Warning Letter Remediation
    • Mock FDA Inspections and Gap Assessment Services
    • Virtual FDA Inspection Consulting
  • Resources
  • News
  • Industries
    • Biologics
    • Cosmetics
    • Dietary Supplements
    • Medical Devices
    • Pet Food and Animal Health
    • Pharmaceuticals
  • Services
    • FDA 483 Response Consulting
    • FDA Inspection Facilitation Services
    • FDA Inspection Readiness Services
    • FDA Inspection Training
    • FDA Warning Letter Remediation
    • Mock FDA Inspections and Gap Assessment Services
    • Virtual FDA Inspection Consulting
  • Resources
  • News
Contact Us

US FDA Issues Warning Letter to DeGrave Dairy for Illegal Drug Residue

  • May 26, 2025

On February 27, 2017, a US Food and Drug Administration (USFDA) Warning Letter was issued to the two owners of DeGrave Dairy. This Warning Letter was issued for violations of the Federal Food, Drug, and Cosmetic Act (the Act).

DeGrave Dairy is a dairy operation that the Minneapolis District inspected for three days.  The violations included

–Presence of Penicillin Residues above limits.

View the full Hospira US FDA Warning Letter

PrevPreviousUS FDA Issues Warning Letter to Lucky Pacific Corp and Kamli International Co. Ltd.
NextTop 10 FDA 483 Observations of 2024—and How to Avoid Them in 2025Next

Latest News and Articles

A validation inspector wearing blue nitrile gloves calibrating an industrial pressure gauge connected to reinforced single-use processing tubes inside a cleanroom.
What Happens During an FDA For-Cause Inspection?
A logistics inspector in gray utility gloves writing on a clipboard to check a shipping manifest and temperature logs at a global container port terminal.
FDA Foreign Inspections Are Increasing Again: What Global Manufacturers Should Expect
A regulatory auditor in gray utility gloves using a rugged mobile tablet to review electronic system audit trails and digital quality data networks inside a pharmaceutical lab.
How FDA Uses AI and Data Analytics During Modern Inspections
A pharmaceutical quality auditor wearing blue nitrile safety gloves executing a surface validation swab on the inner rim of an open stainless steel blending vessel.
The Most Common FDA 483 Observations in Pharmaceutical Manufacturing
A heavy-duty stainless steel chromatography column base connected to clear braided transfer tubes containing clear amber biological harvest fluid within a sterile facility.
How FDA Inspects Viral Vector Manufacturing Facilities
A cleanroom validation technician using a torque wrench to adjust a mechanical valve on an industrial chromatography column unit within a biopharmaceutical plant.
FDA Pre-Approval Inspections (PAIs) for Biologics: Common Readiness Gaps
A corporate compliance director holding a transparent digital glass tablet to cross-reference automated data logs and live facility monitoring streams.
FDA Remote Regulatory Assessments (RRAs): What Biotech Companies Need to Know
A regulatory affairs director and a clinical operator reviewing automated data lineage paths on an interactive luminescent glass panel inside a pharmaceutical facility.
How FDA Investigators Review Batch Records During Drug Inspections
A bioprocess engineer in a full sterile cleanroom suit inspecting single-use bioreactor tubing lines and electronic validation graphs during an mRNA manufacturing facility audit.
How FDA Inspects mRNA and Advanced Therapy Manufacturing Facilities
A corporate regulatory compliance director analyzing global manufacturing data and remote assessment metrics on a transparent digital glass tablet in a high-tech tracking hub.
FDA Inspection Trends in 2026: Biologics, AI, Foreign Facilities, and Remote Assessments

FDA Inspections

Your trusted partner for FDA compliance and inspection readiness. With former ex-FDA’ers  on our team, we provide the expertise and confidence you need to succeed.

  • (208) 971-6430
  • [email protected]

Services

  • Pre-Inspection Prep
  • On-Site Support
  • CAPA Development
  • Staff Training
  • Documentation
  • Emergency Support

Industries

  • Pharmaceuticals
  • Medical Devices
  • Biotechnology
  • Food & Beverage
  • Cosmetics
  • Clinical Research
© 2024 FDA Inspections. All rights reserved.
  • Privacy Policy
  • Terms of Service
  • Disclaimer
THE IMMERSIVE FDA INSPECTION EXPERIENCE →
WARNING LETTERS 483 OBSERVATIONS